IRVINE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit
against Roche Holding AG (“Roche Holding” or the “Company”) (Other OTC:RHHBY). Investors who purchased or otherwise acquired Roche
Holding shares from March 2, 2017 through June 5, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before
the August 7, 2017 lead plaintiff motion deadline.
If you purchased shares of Roche Holding during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000
Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney.
You may also choose to take no action and remain a passive class member.
According to the lawsuit, during the Class Period, Roche Holding issued materially false and misleading statements and/or failed
to disclose material information, specifically that the combination of the Company’s breast cancer drug, Perjeta, and its older
treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer, and has a higher rate of
side effects. Following this news, Roche Holding’s stock price fell materially, which harmed investors according to the
Complaint.
If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please
contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by
e-mail at joon@khanglaw.com.
This press release may be considered Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 joon@khanglaw.com
